证券日报网讯10月17日晚间，凯赛生物发布公告称，截至本公告披露之日，公司完成本次回购，已实际 回购公司股份239，201股，占公司当前总股本721，289，794股的比例为0.0332%。 ...

证券代码：688065 证券简称：凯赛生物 公告编号：2025-059 上海凯赛生物技术股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （二）公司本次实际回购的股份数量、回购价格、使用资金总额符合董事会 审议通过的回购方案，本次股份回购方案实际执行情况与原披露的回购方案不存 在差异，公司已按披露的方案完成回购。 （三）本次实施股份回购使用的资金为公司自有资金或自筹资金，不会对公 司的经营活动、财务状况和未来发展产生重大影响。本次股份回购完成后，不会 导致公司控制权发生变化，回购后公司的股权分布情况符合上市公司的条件，不 会影响公司的上市地位。 三、 回购期间相关主体买卖股票情况 2024 年 10 月 22 日，公司首次披露了回购股份方案，具体内容详见公司在上 海证券交易所网站（www.sse.com.cn）披露的《关于以集中竞价交易方式回购股 份方案公告》（公告编号：2024-056）。 2025 年 1 月 3 日，公司在上海证券交易所网站（www.sse ...

格隆汇10月17日丨凯赛生物(688065.SH)公布，截至本公告披露之日，公司完成本次回购，已实际回购 公司股份23.92万股，占公司当前总股本的比例为0.0332%，回购成交的最高价为53.40元/股，最低价为 44.08元/股，回购均价为45.74元/股，支付的资金总额为人民币1094.14万元（不含交易佣金等交易费 用）。 ...

Core Viewpoint - The article emphasizes the rising importance of biomanufacturing as a strategic and innovative field that disrupts traditional production methods, presenting it as a new growth point for optimizing industrial structures and transforming economic models. The release of the "2025 China Synthetic Biomanufacturing Industry Development White Paper" highlights the current state, trends, and challenges of the biomanufacturing industry in China [1]. Group 1: Current State and Trends - The white paper outlines the development status and trends of biomanufacturing, analyzing the global landscape and key platform facilities [5]. - It compares the biomanufacturing sectors of China and the United States, identifying competitive advantages and areas for improvement [5]. - Future development trends in biomanufacturing are discussed, indicating a shift towards more integrated and innovative approaches [5]. Group 2: Policy Landscape - The report reviews major policies affecting biomanufacturing both domestically and internationally, providing insights into regulatory frameworks that shape the industry [5]. - It categorizes foreign and domestic policies, highlighting their implications for the growth of the biomanufacturing sector [5]. Group 3: Industry Map and Applications - A comprehensive map of the Chinese biomanufacturing industry is presented, detailing key players and their roles [5]. - The report identifies critical application areas for biomanufacturing, including pharmaceuticals, food, personal care, agriculture, chemicals, materials, and energy [5]. Group 4: Key Enterprises and Investment Landscape - The white paper lists the top 10 leading enterprises in China's biomanufacturing sector, showcasing their contributions and market positions [6]. - It also summarizes the strategic directions of 15 publicly listed companies in synthetic biology, along with their investment and development strategies [6]. Group 5: Challenges and Recommendations - The report discusses the challenges faced by the biomanufacturing industry in China, including technological, regulatory, and market-related issues [6]. - Targeted policy recommendations are provided to address these challenges and promote sustainable growth in the biomanufacturing sector [6].

Core Points - Kaisa Bio's stock closed at 48.63 yuan, with a decline of 3.07%, currently in a breaking state [1] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on August 12, 2020, with an initial public offering (IPO) price of 133.45 yuan per share [1][2] - The highest price recorded on the first trading day was 198 yuan, marking the peak since its listing [2] - Kaisa Bio raised a total of 556.06 million yuan during its IPO, with a net amount of 528 million yuan, exceeding the original fundraising plan by 58.11 million yuan [2] - The funds raised are intended for various projects, including a 40,000 tons/year bio-based dodecanedioic acid project and a research center for bio-based polyamide [2] - The total issuance costs for the IPO amounted to 28.06 million yuan, with the underwriter, CITIC Securities, receiving 26.23 million yuan [2] - In July 2022, Kaisa Bio announced a dividend of 4.5 yuan per 10 shares and a stock bonus of 4 shares [2] - The actual controllers of Kaisa Bio are Liu Xiucai, Ma Xiaowen, and Charlie Chi Liu, who are American citizens of Chinese descent [2] - On March 28, 2025, Kaisa Bio disclosed a report on a private placement of A-shares, raising approximately 5.93 billion yuan from its controlling shareholder, Shanghai Yaoxiu [3] - The total amount raised from the two fundraising activities is 11.49 billion yuan [4]

Group 1 - The company held its third extraordinary general meeting of shareholders in 2025, with no resolutions being rejected [2] - The meeting was chaired by Dr. Xiucai Liu, and the procedures complied with the Company Law and the company's articles of association [2][3] - All nine current directors attended the meeting, along with the board secretary and other senior management [3] Group 2 - Three non-cumulative voting proposals were approved: the 2025 Employee Stock Ownership Plan (draft), its management measures, and the authorization for the board to handle related matters [3][4] - The meeting took place on October 15, 2025, at a specified location in Shanghai [3] - The voting results for the proposals were legally valid, and separate counting was conducted for minority investors [4][5]

Core Insights - The A-share private placement market is experiencing a strong recovery in 2025, with total fundraising reaching 775.1 billion yuan in the first three quarters, a year-on-year increase of 548.7% [1][2][10] - Key sectors attracting investment include non-bank financials, defense and military, semiconductors, and hardware equipment [1][3] Fundraising Overview - In the first three quarters of 2025, 119 companies conducted private placements, raising a total of 775.1 billion yuan, marking a 15.53% increase in the number of placements compared to the previous year [2] - The total fundraising amount significantly exceeds the annual totals from the previous three years, which were 721.9 billion yuan in 2022, 578.9 billion yuan in 2023, and 173.1 billion yuan in 2024 [2] Sector Analysis - The banking sector accounted for nearly 70% of the total fundraising, primarily due to major banks like China Bank and Postal Savings Bank raising a combined 520 billion yuan [2][3] - Non-bank financials and public utilities ranked second and third in fundraising, with amounts of 50.7 billion yuan and 29.3 billion yuan, respectively [3] - The semiconductor and defense sectors also saw significant fundraising, with amounts of 25.9 billion yuan and 24.3 billion yuan, respectively [3] Average Fundraising Amount - The average fundraising amount per project has increased, with the average for 115 companies (excluding four state-owned banks) being 22.2 million yuan, compared to 11.9 million yuan in the same period last year [3] - Eleven companies raised over 5 billion yuan each, compared to only four in the previous year [3] Notable Projects - Major projects include Guolian Minsheng's 29.5 billion yuan for asset acquisition, AVIC Chengfei's 17.4 billion yuan for asset acquisition, and China Nuclear Power's 14 billion yuan for project financing [4][6] - Other significant projects include Fulede's 6.19 billion yuan for acquiring 100% of Fulehua and ChipLink's 5.31 billion yuan for acquiring 72.33% of ChipLink Yuezhou [4][6] Regional Distribution - Beijing leads in fundraising with 42.9 billion yuan from 11 projects, accounting for 55.34% of the total [7] - Shanghai and Jiangsu follow with 15.0 billion yuan and 4.3 billion yuan, respectively [7] - Shaanxi has seen a notable increase in fundraising, reaching 19.2 billion yuan, largely due to AVIC Chengfei's successful issuance [8] Market Trends - The recovery in the private placement market is attributed to policy guidance, active mergers and acquisitions, and improved market profitability [12] - The technology sector, particularly in high-end manufacturing and AI, is seeing increased investment, with several companies planning significant fundraising for related projects [12]

上海市锦天城律师事务所 关于上海凯赛生物技术股份有限公司 2025 年第三次临时股东会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海凯赛生物技术股份有限公司 2025 年第三次临时股东会的 法律意见书 致：上海凯赛生物技术股份有限公司 根据《中华人民共和国证券法（2019 年修订）》（以下简称"《证券法》"） 《中华人民共和国公司法（2023 年修订）》（以下简称"《公司法》"）和中 国证券监督管理委员会《上市公司股东会规则》等法律、法规和其他有关规范性 文件的要求，上海市锦天城律师事务所（以下简称"本所"）接受上海凯赛生物 技术股份有限公司（以下简称"凯赛生物"或"公司"）的委托，指派律师参加 公司 2025 年第三次临时股东会（以下简称"本次股东会"或"本次会议"）。 为出具本《法律意见书》，本所声明如下： 1、本所律师仅对本次股东会的召集程序、召开程序、出席会议人员资格、 召集人资格、表决程序、表决结果及会议决 ...

证券代码：688065 证券简称：凯赛生物 公告编号：2025-058 上海凯赛生物技术股份有限公司 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 10 月 15 日 （二） 股东会召开的地点：上海市闵行区绿洲环路 396 弄 11 号 9 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 145 | | --- | --- | | 普通股股东人数 | 145 | | 2、出席会议的股东所持有的表决权数量 | 471,687,692 | | 普通股股东所持有表决权数量 | 471,687,692 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 65.6080 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 65.6080 ...

Core Viewpoint - The article emphasizes the rising importance of biomanufacturing as a strategic and innovative field, which is seen as a new growth point that can drive industrial structure optimization and economic transformation. The release of the "2025 China Synthetic Biomanufacturing Industry Development White Paper" highlights the current state, trends, and challenges of the biomanufacturing industry in China [1]. Group 1: Current State and Trends - The white paper provides an overview of the global biomanufacturing industry, including its development status and trends [5]. - It compares the biomanufacturing sectors of China and the United States, highlighting competitive dynamics [5]. - Future development trends in biomanufacturing are discussed, indicating potential growth areas [5]. Group 2: Policy Landscape - The report outlines major policies affecting biomanufacturing both domestically and internationally for the years 2024-2025 [5]. - It details foreign biomanufacturing industry policies and their implications for the sector [5]. - Domestic policies related to biomanufacturing are also analyzed, providing insights into regulatory frameworks [5]. Group 3: Industry Map and Applications - The white paper presents a comprehensive map of the Chinese biomanufacturing industry, identifying key players and their roles [5]. - It analyzes the biomanufacturing industry chain and key application areas, including pharmaceuticals, food, personal care, agriculture, chemicals, materials, and energy [5][6]. - Specific applications of biomanufacturing in various sectors are highlighted, showcasing its versatility and potential impact [5]. Group 4: Key Enterprises and Investment Landscape - The report identifies ten leading enterprises in the Chinese biomanufacturing industry, providing insights into their operations and market positions [6]. - It summarizes the strategic directions of 15 listed companies in synthetic biology, indicating their focus areas and growth strategies [6]. - The investment landscape for synthetic biology in China is examined, detailing funding trends and opportunities from 2024 to mid-2025 [6]. Group 5: Challenges and Recommendations - The white paper discusses the challenges faced by the biomanufacturing industry in China, including technological, regulatory, and market-related issues [6]. - It offers targeted policy recommendations to address these challenges, aiming to support the sustainable development of the biomanufacturing sector [6].